Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer
| Autor: | Olivier Colomban, Michel Tod, David Benayoun, Pierre-Adrien Bolze, Benoit You, François Golfier, Simon Ducoulombier |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty medicine.medical_treatment FIGO Stage IIIC Population Kaplan-Meier Estimate 03 medical and health sciences 0302 clinical medicine Elimination rate constant Risk Factors Internal medicine medicine Humans Relapse risk education Aged Aged 80 and over Ovarian Neoplasms education.field_of_study Chemotherapy 030219 obstetrics & reproductive medicine business.industry Retrospective cohort study General Medicine Cytoreduction Surgical Procedures Middle Aged medicine.disease Prognosis Neoadjuvant Therapy Kinetics 030220 oncology & carcinogenesis CA-125 Antigen Surgery outcome Female Neoplasm Recurrence Local Ovarian cancer business |
| Zdroj: | Anticancer research. 37(12) |
| ISSN: | 1791-7530 |
| Popis: | Aim To investigate the prognostic value of modeled CA-125 kinetic parameters regarding surgery outcomes and time to second-line chemotherapy in a population of ovarian cancer patients treated with neoadjuvant chemotherapy followed by interval cytoreduction. Patients and methods This retrospective study included consecutive patients with FIGO stage IIIc/IV ovarian cancer treated between 2006 and 2014. We characterized CA-125 kinetics and identified modeled kinetic parameters. Results Fifty four patients were included. KELIM (modeled CA-125 elimination rate constant) was an independent predictive parameter of optimal cytoreduction (OR=0.18; 95% CI=0.04-0.69; p=0.02). In the optimal cytoreduction population (40 patients, 74.1%), E50 (concentration producing 50% of the maximum chemotherapy effect) was a significant prognostic parameter regarding time to second-line chemotherapy (HR=0.38; 95% CI=0.173-0.854; p=0.019). Conclusion We identified CA-125 modeled kinetic parameters during neoadjuvant chemotherapy harboring potential predictive values regarding the likelihood of optimal cytoreduction, along with time to second-line chemotherapy in optimally-cytoreduced patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|